Home Contact Us 中文 English
Yourlocation:Home >News> Trimebutine maleate combined with domperidone for treatment

Trimebutine maleate combined with domperidone for treatment

Time:2015/9/30 7:20:52

To assess the clinical effects of trimebutine maleate combined with domperidone in the treatment of diabetic gastroparesis(DGP).METHODS: Eighty-six patients with DGP were randomly divided into either an experiment group or a control group. The experiment group was treated with trimebutine maleate combined with domperidone, and the control group was treated with domperidone alone. The clinical effects, gastric emptying half-time(GET1/2), adverse reactions, and relapse were compared for the two groups.RESULTS: The total effective rate for the experiment group was significantly higher than that for the control group(93.02% vs 74.42%, P 0.05). The GET1/2 post-treatment for the two groups was significantly lower than that priortreatment(124.49 min ± 23.05 min vs 225.62 min± 21.88 min, 199.46 min ± 23.49 min vs 222.62 min ± 19.08 min, P 0.05). There was no significant difference in the rate of adverse reactions for the two groups(0.00% vs 4.65%, P 0.05). The rate of relapse at 2 mo for the experiment group was lower than that for the control group(13.95% vs 51.16%, P 0.05).CONCLUSION: Trimebutine maleate combined with domperidone can improve clinical symptoms and GET1/2 in patients with DGP.